OraSure Technologies, Inc. (NASDAQ:OSUR) was downgraded by stock analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a research report issued on Monday, July 24th.
A number of other research analysts have also recently commented on OSUR. Jefferies Group LLC upped their price target on shares of OraSure Technologies from $16.00 to $19.00 and gave the stock a “buy” rating in a report on Wednesday, June 28th. Stephens reaffirmed an “overweight” rating and issued a $19.00 price objective (up from $14.00) on shares of OraSure Technologies in a research note on Tuesday, July 11th. Canaccord Genuity upped their price objective on shares of OraSure Technologies from $15.00 to $18.00 and gave the stock a “buy” rating in a research note on Wednesday, June 28th. Finally, Zacks Investment Research lowered shares of OraSure Technologies from a “buy” rating to a “hold” rating in a research note on Wednesday, April 12th. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. OraSure Technologies has an average rating of “Buy” and an average target price of $15.46.
Shares of OraSure Technologies (OSUR) traded up 1.45% during midday trading on Monday, reaching $20.26. 863,698 shares of the company’s stock were exchanged. The stock has a market cap of $1.20 billion, a PE ratio of 37.45 and a beta of 1.57. The stock’s 50 day moving average is $18.98 and its 200-day moving average is $14.50. OraSure Technologies has a 12-month low of $6.87 and a 12-month high of $21.59.
OraSure Technologies (NASDAQ:OSUR) last posted its quarterly earnings results on Wednesday, August 2nd. The medical instruments supplier reported $0.09 EPS for the quarter, topping the Zacks’ consensus estimate of $0.07 by $0.02. The firm had revenue of $40.18 million for the quarter, compared to analysts’ expectations of $36.54 million. OraSure Technologies had a net margin of 22.29% and a return on equity of 15.64%. The business’s revenue for the quarter was up 28.1% on a year-over-year basis. During the same period in the prior year, the business posted $0.07 earnings per share. On average, equities analysts expect that OraSure Technologies will post $0.48 EPS for the current year.
In other OraSure Technologies news, Director Ronny B. Lancaster sold 89,684 shares of the stock in a transaction dated Tuesday, May 30th. The shares were sold at an average price of $14.79, for a total transaction of $1,326,426.36. Following the completion of the sale, the director now directly owns 6,295 shares of the company’s stock, valued at $93,103.05. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Douglas A. Michels sold 290,495 shares of the stock in a transaction dated Tuesday, June 27th. The shares were sold at an average price of $16.75, for a total transaction of $4,865,791.25. Following the sale, the chief executive officer now directly owns 894,012 shares of the company’s stock, valued at $14,974,701. The disclosure for this sale can be found here. Over the last three months, insiders have sold 1,036,670 shares of company stock valued at $19,807,152. Insiders own 7.80% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the stock. Victory Capital Management Inc. purchased a new stake in OraSure Technologies during the first quarter valued at approximately $100,000. First Mercantile Trust Co. purchased a new stake in OraSure Technologies during the second quarter valued at approximately $104,000. Pinebridge Investments L.P. purchased a new stake in OraSure Technologies during the second quarter valued at approximately $131,000. Private Advisor Group LLC raised its stake in OraSure Technologies by 7.1% in the first quarter. Private Advisor Group LLC now owns 10,923 shares of the medical instruments supplier’s stock valued at $135,000 after buying an additional 723 shares during the last quarter. Finally, Profund Advisors LLC purchased a new stake in OraSure Technologies during the first quarter valued at approximately $137,000. 89.76% of the stock is owned by institutional investors and hedge funds.
About OraSure Technologies
OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.
Receive News & Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.